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Elective Chronic Total
Coronary Occlusion
AngioplastyIn the paper by George et al. (1), regarding the clinical
outcome after chronic total occlusion (CTO) percu-
taneous coronary intervention (PCI), the methods
have been described with insufﬁcient details and no
data are provided about the indication to PCI and the
viability of the myocardial territory supplied by the
CTO vessel (1). Moreover, beyond the characteristics
of the medical treatment after PCI that were un-
known, patients with successful PCI had nonuniform
procedural treatment with a substantial minority of
patients receiving bare-metal stents or no stent. All
these variables might have confounded the results
considering the strong impact on survival of optimal
medical treatment and drug-eluting stents after CTO
PCI. The authors revealed a survival beneﬁt after CTO
PCI success, and a greater survival improvement in
patients who received a complete revascularization.
It should have been outlined that patients with a
CTO and single-vessel disease have a very low mor-
tality rate and it is likely that the outcome cannot
be improved by successful PCI. Conversely, the
beneﬁt of a complete revascularization is easily
revealed in patients with at least 1 CTO and multi-
vessel disease. The link between completeness of
revascularization and improved survival just in pa-
tients with CTO and multivessel disease was already
demonstrated by 2 key studies that are not com-
mented on or quoted by the authors (2,3). Finally, it
seems unlikely that the ongoing EuroCTO (European
Chronic Total Occlusion) study comparing CTO PCIwith optimal medical therapy alone will deﬁnitely
support the indication to CTO revascularization,
considering the very low enrollment rate of this
study and the subsequent biased patient selection,
and the strong rationale of revascularization of
a CTO vessel supplying a large amount of viable
myocardium.*David Antoniucci, MD
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2013;61:282–94.REPLY: Long-Term Follow-Up of Elective
Chronic Total Coronary Occlusion AngioplastyWe thank the readers of the Journal for their
thoughtful comments about our paper (1). We carried
out a retrospective analysis of registry data concern-
ing chronic total occlusion (CTO) procedures. In
keeping with other International Procedural Regis-
tries, no data exist in the British Cardiovascular
Intervention Society dataset for patients in whom
revascularization was not attempted. In view of this,
we have been careful not to attribute causality; we
have simply described the association. This was not a
randomized trial.
Dr. Huqi and colleagues suggest that our work is
consistent with previous work by Boden et al. (2),
which examined medical management versus percu-
taneous coronary intervention (PCI). That study is not
representative of our patient population, as they
excluded patients whose coronary anatomy was not
considered suitable for successful PCI (as is the case
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2710for many patients with CTOs). Although the mortality
curves for partial and complete revascularization
brieﬂy overlap, there is a signiﬁcant statistical dif-
ference between them. Therefore, the statement that
the greatest difference was observed among patients
with complete revascularization is correct.
In response to Dr. Antoniucci and colleagues, the
vast majority of the interventions (>95%) were carried
out for treatment of angina in stable patients. Patient
management was according to the standard practice of
the clinicians in each institution, and therefore pre-
procedural myocardial viability assessment and type
of stent used varied. They state that there is a “strong
impact on survival of. drug-eluting stents after CTO
PCI” but then go on to add that “patients with a CTO
and single-vessel disease have a very low mortality
rate and it is likely that the outcome cannot be
improved by successful PCI.” These statements seem
at odds with each other, which is not helped by the
ﬁnal assertion that there is a “strong rationale for
revascularization of a CTO vessel supplying a large
amount of viable myocardium.” Which is correct?
Although the European Chronic Total Occlusion Study
is indeed recruiting slowly, we are hopeful that with
long enough follow-up, useful data will emerge.
We fully agree with Dr. Hiser’s excellent letter and
the statement that “one cannot imply beneﬁt of
revascularization because those with successful
interventions do better than those with failed in-
terventions.” We drew attention to this brieﬂy in the
second paragraph of the discussion; it is indeed
possible that disease burden dictates the outcome
rather than success or failure of the procedure. This is
why we have stated the differences observed without
implying causation. This is also why randomized tri-
als are required in this area and why the EuroCTO
(European Chronic Total Occlusion) trial is important.*Sudhakar George, MD
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Time to Reassess the Speciﬁc Impact of Drug
Therapy in Coronary Heart Disease PatientsRecently b-blocker drugs have been accepted as the
standard of care for angina and coronary heart dis-
ease, especially when patients have had myocardial
infarction. However, the ﬁnding by Andersson et al.
(1) on b-blocker effects only in recent myocardial in-
farcts opens an interesting question in cardiovascular
pharmacology, in which 2 major points deserve
consideration.
First, the references in Andersson et al. (1) demon-
strated that treatment with b-blockers had no statis-
tically signiﬁcant impact on mortality compared to
placebo or other active comparator in clinical trials for
patients with stable angina (Ref. 7 in the Andersson
et al. article), and were not associated with lower
incidence of cardiovascular events in patients with
previous history of myocardial infarction (MI), among
patients with coronary heart disease (CHD) but no
history of MI, or among patients with risk factors for
atherosclerotic disease only (44,708 subjects) (Ref. 8
in the Andersson et al. article).
With further reﬁnement, the AVANCE Register
study (2,024 angina patients in stable condition, 419
cardiologists) (2) found that despite b-blockers (75%
to 79%), statins (90% to 93%), antiplatelets (95% to
97%), nitrates (61% to 100%), and calcium antagonists
(44%), a higher proportion of patients had angina
(49.3%), including those with revascularization (66%)
who had angina (59%). In addition, patients per-
ceived their condition as being more serious than
their physicians, independently of symptom in-
tensity, suggesting that the optimal target for quality
of life or angina has not been currently achieved.
